Expertise in
5
conditions

Dr. Paul Harari

Radiation Oncology
University Hospital
600 Highland Ave, 
Madison, WI 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
5
conditions
University Hospital
600 Highland Ave, 
Madison, WI 

Overview

Paul Harari is a Radiation Oncologist practicing medicine in Madison, Wisconsin.

Dr. Harari is highly rated in 5 conditions, according to our data. His clinical expertise encompasses Head and Neck Squamous Cell Carcinoma (HNSCC), Human Papillomavirus Infection, Adenoid Cystic Carcinoma, Throat Cancer, and Gastrostomy.

He is actively involved in clinical research, co-authoring 155 peer reviewed articles and participating in 10 clinical trials.

Specialties

Radiation Oncology

Licenses

Radiology in WI

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Aspirus Arise Health
  • HMO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Quartz
  • HMO
  • POS
  • PPO
Security Health
  • EPO
  • HMO
  • INDEMNITY
  • POS

Locations

University Hospital
600 Highland Ave, Madison, WI 53792
Other Locations
UW Medical Foundation
7974 Uw Health Ct, Middleton, WI 53562

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
Enrollment Status: Recruiting
Publish Date: April 15, 2026
Intervention Type: Procedure, Drug, Other, Radiation, Biological
Study Drugs: Atezolizumab, Cetuximab, Cisplatin, Docetaxel
Study Phase: Phase 2/Phase 3
Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)
Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)
Enrollment Status: Active_not_recruiting
Publish Date: April 03, 2026
Intervention Type: Other, Drug, Radiation
Study Drugs: Cisplatin, Fluorouracil, Gemcitabine Hydrochloride, Paclitaxel
Study Phase: Phase 2/Phase 3
Randomized Phase II/III Trial of Radiation With Cisplatin at 100 mg/m2 Every Three Weeks Versus Radiation With Weekly Cisplatin at 40 mg/m2 for Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Randomized Phase II/III Trial of Radiation With Cisplatin at 100 mg/m2 Every Three Weeks Versus Radiation With Weekly Cisplatin at 40 mg/m2 for Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Enrollment Status: Suspended
Publish Date: April 03, 2026
Intervention Type: Other, Procedure, Drug, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2/Phase 3
Phase II Randomized Trial of Transoral Surgical Resection Followed by Low-Dose or Standard-Dose IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer
Phase II Randomized Trial of Transoral Surgical Resection Followed by Low-Dose or Standard-Dose IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 01, 2026
Intervention Type: Drug, Radiation, Procedure
Study Drugs: Cisplatin, Carboplatin
Study Phase: Phase 2
A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 06, 2026
Intervention Type: Biological, Radiation
Study Drug: Cetuximab
Study Phase: Phase 3
A Randomized Phase II Trial for Patients With p16 Positive, Non-Smoking Associated, Locoregionally Advanced Oropharyngeal Cancer
A Randomized Phase II Trial for Patients With p16 Positive, Non-Smoking Associated, Locoregionally Advanced Oropharyngeal Cancer
Enrollment Status: Completed
Publish Date: October 09, 2025
Intervention Type: Drug, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
A Randomized Phase II/Phase III Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors
A Randomized Phase II/Phase III Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors
Enrollment Status: Active_not_recruiting
Publish Date: February 13, 2025
Intervention Type: Drug, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
TRYHARD: A Phase II, Randomized, Double Blind, Placebo-Controlled Study of Lapatinib (Tykerb®) for Non-HPV Locally Advanced Head and Neck Cancer With Concurrent Chemoradiation
TRYHARD: A Phase II, Randomized, Double Blind, Placebo-Controlled Study of Lapatinib (Tykerb®) for Non-HPV Locally Advanced Head and Neck Cancer With Concurrent Chemoradiation
Enrollment Status: Completed
Publish Date: October 17, 2023
Intervention Type: Drug, Radiation
Study Drugs: Cisplatin, Lapatinib
Study Phase: Phase 2
Phase IIB Randomized, Placebo-Controlled Trial of ACTOplus Met® XR in Subjects With Stage I-IV Squamous Cell Carcinoma of the Oral Cavity or Oropharynx Prior to Definitive Treatment
Phase IIB Randomized, Placebo-Controlled Trial of ACTOplus Met® XR in Subjects With Stage I-IV Squamous Cell Carcinoma of the Oral Cavity or Oropharynx Prior to Definitive Treatment
Enrollment Status: Terminated
Publish Date: March 08, 2023
Intervention Type: Other, Drug
Study Phase: Phase 2
PET/MRI to Enhance Precision Guidance in Head and Neck Radiation Treatment Planning
PET/MRI to Enhance Precision Guidance in Head and Neck Radiation Treatment Planning
Enrollment Status: Terminated
Publish Date: November 21, 2019
Intervention Type: Device
View 9 Less Clinical Trials

155 Total Publications

Quality of life in patients with p16+ oropharyngeal cancer receiving accelerated radiotherapy with either cisplatin or cetuximab in the NRG/RTOG 1016 randomized controlled trial.
Quality of life in patients with p16+ oropharyngeal cancer receiving accelerated radiotherapy with either cisplatin or cetuximab in the NRG/RTOG 1016 randomized controlled trial.
Journal: International journal of radiation oncology, biology, physics
Published: August 28, 2025
Similar Doctors
Expertise in
14
conditions
Dr. Andrew Baschnagel
Radiation Oncology
Expertise in
14
conditions
Dr. Andrew Baschnagel
Radiation Oncology

University Hospital

600 Highland Ave, 
Madison, WI 
 (0.1 miles away)
608-263-8500
Experience:
17+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Andrew Baschnagel is a Radiation Oncologist practicing medicine in Madison, Wisconsin. He has been practicing medicine for over 17 years. Dr. Baschnagel is highly rated in 14 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), Pleuropulmonary Blastoma, and Gamma Knife Radiosurgery.

Expertise in
31
conditions
Dr. Steven Howard
Radiation Oncology
Expertise in
31
conditions
Dr. Steven Howard
Radiation Oncology

University Hospital

600 Highland Ave, 
Madison, WI 
 (0.1 miles away)
608-263-8500
Languages Spoken:
English
See accepted insurances

Steven Howard is a Radiation Oncologist practicing medicine in Madison, Wisconsin. Dr. Howard is highly rated in 31 conditions, according to our data. His clinical expertise encompasses Glioblastoma, Astrocytoma, Brain Tumor, Glioma, and Rhizotomy.

Expertise in
12
conditions
Dr. Kristin Bradley
Radiation Oncology
Expertise in
12
conditions
Dr. Kristin Bradley
Radiation Oncology

University Hospital

600 Highland Ave, 
Madison, WI 
 (0.1 miles away)
608-263-8500
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Kristin Bradley is a Radiation Oncologist practicing medicine in Madison, Wisconsin. Dr. Bradley is highly rated in 12 conditions, according to our data. Her clinical expertise encompasses Cervical Cancer, Endometrial Cancer, Vaginal Cancer, and Neuroendocrine Carcinoma of the Cervix.

Frequently Asked Questions about Dr. Paul Harari

How do I make an appointment with Dr. Paul Harari?

You can book an appointment with Dr. Paul Harari by calling their office at 608-263-8500. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Paul Harari a top-rated expert for Head and Neck Squamous Cell Carcinoma (HNSCC)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Paul Harari is classified as an Elite expert for Head and Neck Squamous Cell Carcinoma (HNSCC), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Paul Harari specialize in?

While Dr. Paul Harari is a Radiation Oncology, they have specific expertise in Head and Neck Squamous Cell Carcinoma (HNSCC), Human Papillomavirus Infection, and Adenoid Cystic Carcinoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Radiation Oncology.

Does Dr. Paul Harari participate in research or clinical trials?

Yes. Dr. Paul Harari has published 155 articles and abstracts on conditions like Head and Neck Squamous Cell Carcinoma (HNSCC). You can view a list of Dr. Paul Harari's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Paul Harari accept my insurance?

Dr. Paul Harari accepts most major insurance plans, including Anthem BCBS and Aspirus Arise Health. We recommend calling the office directly at 608-263-8500 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Harari's expertise for a condition
ConditionClose
View All 17 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile